What it is
LIPO C+ is a lipotropic injection — a ready-mixed solution of vitamins, nutrients, and amino acids meant to shift how the body handles fat — with a stimulant added to it.
It gives a focused, alert kind of energy along with mild to moderate appetite suppression. That energy is stimulant-type, and somewhat less potent than Lipo Shredder, the strongest product in this line.
It has eight ingredients:
ATP — adenosine triphosphate, the molecule cells actually spend when they use energy. It boosts energy and enhances muscular energy output.
Eria jarensis — a mild stimulant taken from an orchid species of that name. It enhances energy, focus, and mood, and suppresses appetite. This is the ingredient that makes this product different from plain Lipo-C, and it is the reason for most of the warnings further down.
L-carnitine — carries fatty acids into the mitochondria, the parts of the cell that turn fuel into energy, where they are burned to make ATP.
Methionine — an amino acid that supports liver function and fat metabolism, and feeds production of glutathione, the body's main built-in antioxidant.
Choline — exports fat out of the liver and stops fat accumulating there. It also supports thinking and memory.
Inositol — improves blood fat levels, improves insulin sensitivity and metabolic regulation, and stabilises mood.
Lidocaine — a local anaesthetic, included so the injection hurts less.
Benzyl alcohol — a preservative that also acts as a co-solvent and stabiliser.
The vial comes ready-mixed. Nothing is reconstituted. You draw a dose and inject it into a muscle, an intramuscular injection.
A stimulant-containing lipotropic for intramuscular administration — the Lipo-C base with Eria jarensis, ATP, and inositol added, dexpanthenol dropped, and lidocaine plus benzyl alcohol in the vehicle. It is positioned as delivering focused, alert energy with mild-to-moderate appetite suppression, and as a step below Lipo Shredder in stimulant potency.
Declared constituents and their stated roles:
ATP — primary substrate for cellular energy use and storage; enhances muscular energy output.
Eria jarensis — mild stimulant from the Eria jarensis orchid; enhances energy, focus, and mood; appetite suppressant. It behaves similarly to phenethylamine derivatives, which is the basis of its stimulant interaction list.
L-carnitine — mitochondrial transport of fatty acids for ATP conversion; direct role in fat utilisation.
Methionine — hepatic function and fat metabolism support; substrate for glutathione synthesis.
Choline — hepatic fat export; prevention of hepatic fat accumulation; cognitive support.
Inositol — improved lipid profile, insulin sensitivity, and metabolic regulation; mood stabilisation.
Lidocaine — local anaesthetic for injection comfort. It is also a sodium channel blocker, and the interaction list below treats it as cardiac-relevant at higher exposure.
Benzyl alcohol — antimicrobial preservative and co-solvent/stabiliser.
No quantities are declared for any constituent, which is the central limitation here: the cardiovascular and stimulant warnings below cannot be sized against a dose.
What it does
Two things at once.
The lipotropic half works on fat. Choline moves fat out of the liver; carnitine carries fatty acids into the parts of the cell that burn them; methionine and inositol support the liver and the metabolic regulation around it.
The stimulant half works on the nervous system. Eria jarensis raises energy, focus, and mood, and reduces appetite. ATP adds to the energy side. The overall effect is focused, alert energy with mild to moderate appetite suppression.
Inositol also improves insulin sensitivity and blood fat levels, which is a metabolic effect rather than a stimulant one.
Lidocaine does nothing metabolic — it is there so the shot hurts less.
Two mechanistically separate arms in one vial.
Lipotropic arm: choline-driven hepatic fat export, carnitine-driven mitochondrial long-chain fatty-acid import, methionine supporting transmethylation and glutathione supply, inositol acting on insulin sensitivity and lipid profile.
Sympathomimetic arm: Eria jarensis, which behaves similarly to phenethylamine derivatives — hence energy, focus, mood elevation, and appetite suppression, and hence the interaction profile. ATP contributes on the energy side and, per the interaction list, causes vasodilation and can affect cardiac conduction.
The claimed result is focused, alert energy with mild-to-moderate appetite suppression, positioned as less potent than the albuterol-containing Lipo Shredder.
Lidocaine is non-metabolic — injection comfort only — but it is not pharmacologically inert, and the cardiovascular interaction list names it as a sodium channel blocker affecting cardiac conduction at higher exposure.
Benefits
Evidence grades: what the labels mean
- Human trials Supported by randomised or placebo-controlled human trials.
- Limited human data Some human evidence, such as pilot studies, case reports or observational data, but no controlled trials.
- Animal or lab only Shown in animal or cell studies only; not yet tested in people.
- Anecdotal No published studies; based on user reports or theory.
Each grade reflects the strongest published support for that specific claim, not for the compound as a whole.
- Supports fat loss — the product is described as ideal for people looking to support it.Limited human data
- Gives a focused, alert kind of energy.Anecdotal
- Suppresses appetite mildly to moderately.Anecdotal
- Improves energy levels generally, and optimises metabolic function.Anecdotal
- Gives performance and thinking benefits alongside the physical ones.Anecdotal
- Boosts muscular energy output, from the ATP component.Limited human data
- Supports liver function and fat metabolism, and feeds antioxidant production, from the methionine component.Animal or lab only
- Stops fat accumulating in the liver and exports what is there, from the choline component.Limited human data
- Improves blood fat levels, insulin sensitivity, and mood stability, from the inositol component.Limited human data
- Hurts less to inject than it otherwise would, because lidocaine is in the formula.Human trials
- Fat loss support — the primary indication.Limited human data
- Focused, alert energy of a stimulant character, with mild-to-moderate appetite suppression.Anecdotal
- Improved energy levels and metabolic function optimisation.Anecdotal
- Physiological plus performance and cognitive benefits.Anecdotal
- Enhanced muscular energy output (ATP).Limited human data
- Hepatic function and fat metabolism support with glutathione substrate supply (methionine).Animal or lab only
- Hepatic fat export and prevention of hepatic fat accumulation, plus cognitive support (choline).Limited human data
- Improved lipid profile, insulin sensitivity, metabolic regulation, and mood stabilisation (inositol).Limited human data
- Reduced injection discomfort from included lidocaine — a formulation benefit rather than a pharmacological one.Human trials
- Positioned as less stimulant-potent than Lipo Shredder, which is a benefit for anyone who found that product too strong.Anecdotal
Reconstitution and dosing
Storage first: do not refrigerate or freeze this product, before or after use.
The vial comes ready-mixed. Nothing is reconstituted.
Intramuscular injection is preferred. Subcutaneous — just under the skin — is allowed, but it is substantially less effective.
Dose in the morning, so it does not disturb your sleep. Fasting is not necessary.
A cycle is 8 weeks or more, followed by a break at least half the length of the cycle you ran.
The standard dose is 50 to 100 units once a day, 2 to 3 days a week. The advanced dose is 50 to 150 units once a day, 3 to 5 days a week.
If crystals form. This is expected. Everything in this lipolytic line is highly concentrated, and L-carnitine in particular crystallises readily when cold. This is a normal physical change and does not mean contamination, spoilage, or lost potency — and there are no peptides in this formulation. To dissolve crystals: let the vial reach room temperature naturally over several hours, swirl it gently now and then, use a lukewarm water bath at about 90–110°F for 10 to 20 minutes, and alternate warming and gentle mixing if either alone is not working. Then store at a stable temperature, because repeated cooling and warming encourages crystals to come back.
What not to do with a crystallised vial: do not microwave it, do not boil it or expose it to strong heat, and do not shake it.
Why the table shows a milligram figure you should ignore. The dose is 50 to 150 units, with a microgram figure beside it — 500 to 1,500 mcg. Those two together imply a milligram of material in each millilitre of solution. The vial size, vial mass, and amount of any single ingredient are not specified. So the table below is anchored to a stand-in vial of 10 mg in 10 mL, which exists purely to make the draw column show the same unit numbers as the dosing schedule. The milligram column is arithmetic scaffolding, not a fact about your vial.
And there is a bigger gap behind it. This formula contains a stimulant, and the interaction list further up this page is long because of it. To use that list properly you would need to know how much Eria jarensis is in a dose — and no quantity is given for it or for anything else. You are asked to be cautious about a dose that is never stated.
Storage: never refrigerate or freeze, before or after use.
Pre-mixed solution; no reconstitution step.
Intramuscular administration preferred. Subcutaneous permitted but substantially less effective.
Morning dosing to avoid sleep disturbance. Fasting not necessary.
Cycle: 8 weeks or more, washout at least half the completed cycle length.
Standard protocol: 50–100 units 1×/day, 2–3 days per week. Advanced protocol: 50–150 units 1×/day, 3–5 days per week. Identical to Lipo-C's schedule.
Crystallisation. Expected behaviour across the lipolytic line given high total solute concentration, with L-carnitine the main offender. It is a physical change, not contamination, spoilage, or potency loss, and the formulation contains no peptides. Recovery: natural warming to room temperature over several hours; periodic gentle swirling, avoiding vigorous shaking and the foaming it causes; a lukewarm water bath at 90–110°F (32–43°C) for 10–20 minutes; alternating warming and gentle mixing where either alone fails. Then hold at a stable temperature — thermal cycling promotes re-formation. Prohibited: microwaving, boiling or excessive heat, shaking.
Concentration basis. 50–100 units against 500–1,000 mcg implies 10 mcg per insulin unit, 1 mg/mL. No vial volume, mass, or per-constituent quantity appears anywhere. The protocols carry a placeholder of 10 mg in 10 mL encoding that ratio; computed draws reproduce the scheduled unit figures exactly, and the vial dimensions carry no information.
The arithmetic problem here is sharper than for the non-stimulant lipotropics. A milligram per millilitre cannot plausibly accommodate eight declared constituents at any meaningful dose, and none of them is declared individually. The consequence is specific rather than academic: the sympathomimetic exposure per injection is not derivable, and an interaction list naming MAOIs, amphetamines, antiarrhythmics, and beta blockers is difficult to act on without it. Lidocaine sits in the same blind spot — it is a sodium channel blocker the cardiac interaction section treats as dose-relevant at higher exposure, and its quantity is likewise unstated.
Standard protocol
Supplied as a ready-mixed solution — nothing to reconstitute. No vial size, mass, or per-ingredient quantities are specified; the 10 mg in 10 mL shown here is a placeholder that reproduces the figure of 10 mcg per insulin unit, so the draw column matches the dosing schedule exactly. Never refrigerate or freeze.
1 mg/mL · 10 mcg per unit
Cycle: 8 weeks or more, then a washout of at least half the cycle length · Frequency: 1×/day, 2–3 days per week; intramuscular preferred, subcutaneous allowed but substantially less effective; morning; fasting not required
| When | Dose | Draw | How often |
|---|---|---|---|
| 50 units — low end of the 50–100 unit range | 500 mcg | 50 units | 1×/day, 2–3 days per week |
| 100 units — top of the range | 1 mg | 100 units | 1×/day, 2–3 days per week |
Advanced protocol
Ready-mixed solution; no reconstitution. The 10 mg in 10 mL is a placeholder reproducing the stated 10 mcg per insulin unit — no vial size or mass is specified. Never refrigerate or freeze.
1 mg/mL · 10 mcg per unit
Cycle: 8 weeks or more, then a washout of at least half the cycle length · Frequency: 1×/day, 3–5 days per week; intramuscular preferred; morning; fasting not required
| When | Dose | Draw | How often |
|---|---|---|---|
| 50 units — low end of the 50–150 unit range | 500 mcg | 50 units | 1×/day, 3–5 days per week |
| 150 units — top of the range | 1.5 mg | 150 units(over 100 units: split across 2 syringes) | 1×/day, 3–5 days per week |
10 mg in 10 mL is 1 mg/mL, or 10 mcg per unit. Draw 50 units (0.5 mL) for 500 mcg.
Who should avoid it
- Anyone pregnant or breastfeeding.
- Anyone taking an MAOI — a monoamine oxidase inhibitor, an older class of antidepressant that includes phenelzine and tranylcypromine.
- Anyone who has recently had a cardiovascular event such as a heart attack or a stroke.
- Anyone hypersensitive to lidocaine or to benzyl alcohol, both of which are in the vial.
- Anyone with uncontrolled high blood pressure, or an active heart rhythm disorder.
- Use only with caution, and under direct medical supervision, if you have an anxiety or panic disorder — the stimulant component may make attacks worse or more frequent.
- Use only with caution, and under direct medical supervision, if you have an overactive thyroid, because that raises sensitivity to stimulants.
- Use only with caution, and under direct medical supervision, if you have liver disease, because lipotropics place a load on the liver's metabolism.
- Interaction — proceed with extreme caution combining this with other stimulants, because Eria jarensis behaves like the phenethylamine family. These include caffeine, ephedrine, DMAA and DMHA, albuterol, amphetamine, methamphetamine, methylphenidate, phenelzine, tranylcypromine, pseudoephedrine, and phenylephrine.
- Interaction — the ATP in the formula causes blood vessels to widen and can affect the heart's electrical conduction.
- Interaction — the lidocaine in the formula blocks sodium channels and affects the heart's electrical conduction at higher exposure.
- Interaction — antiarrhythmic drugs, the medicines that control heart rhythm. Examples are amiodarone and flecainide.
- Interaction — beta blockers and calcium channel blockers, both blood pressure medicines. The combination may exaggerate low blood pressure or a slow heart rate.
- Interaction — nitrates and other vasodilators, which widen blood vessels. The effects add together, leading to dizziness and low blood pressure.
- Interaction — drugs the liver has to process, such as statins, some antidepressants, and some anticonvulsants (anti-seizure medicines). Lipotropics add to the methylation and liver load, and how those drugs are broken down may change. This is typically mild, but relevant where liver function is already compromised.
- Interaction — high-dose niacin, or other compounds that are hard on the liver, may add to the liver stress.
- Interaction — levodopa taken without carbidopa, for Parkinson's disease. Vitamin B6 (pyridoxine) reduces its effectiveness.
- Interaction — SSRIs (selective serotonin reuptake inhibitors, the most commonly prescribed family of antidepressants), antipsychotics, and other drugs that act on the central nervous system. Combined with a stimulant they may cause unpredictable stimulation or anxiety.
- Watch for clusters of symptoms that suggest an interaction is going wrong. A fast heart rate, palpitations, and raised blood pressure together point to a cardiovascular interaction.
- Watch for the other cluster: anxiety or agitation, insomnia, and headache together point to a central nervous system interaction.
- Note: the B6 interaction is listed even though vitamin B6 does not appear anywhere in this product's ingredient list. Either the ingredient list is incomplete or the interaction applies to a different formula, and there is no way to tell which.
- Note: no quantities are given for any ingredient. That means there is no way to judge how strong the stimulant dose is, which is the single most useful number for deciding whether any of the cautions above apply to you.
- Note: the standalone L-Carnitine page on this site contraindicates cardiovascular disease, arrhythmia, uncontrolled hypertension, stimulant sensitivity, anxiety or panic disorder, epilepsy, and pregnancy or breastfeeding. Most of those already appear above. Epilepsy does not — the standalone entry notes that L-carnitine may increase seizure frequency in people with epilepsy, and that applies here too.
- Pregnancy and lactation — contraindicated.
- Concurrent MAOI therapy — contraindicated.
- Recent cardiovascular event (myocardial infarction, stroke) — contraindicated.
- Hypersensitivity to lidocaine or benzyl alcohol — contraindicated; both are in the vehicle.
- Uncontrolled hypertension or active cardiac arrhythmia — contraindicated.
- Anxiety or panic disorder — use only under direct medical supervision; the stimulant component may increase incident severity and frequency.
- Hyperthyroidism — use only under direct medical supervision; increased stimulant sensitivity.
- Hepatic disease — use only under direct medical supervision, given the lipotropic metabolic burden.
- Stimulant interactions, requiring extreme caution because Eria jarensis behaves similarly to phenethylamine derivatives: caffeine, ephedrine, DMAA/DMHA, albuterol, amphetamine, methamphetamine, methylphenidate, phenelzine, tranylcypromine, pseudoephedrine, phenylephrine.
- Cardiovascular and electrophysiological interaction from ATP itself: vasodilation with potential effect on cardiac conduction.
- Cardiovascular and electrophysiological interaction from lidocaine itself: sodium channel blockade affecting cardiac conduction at higher exposure.
- Antiarrhythmics — amiodarone, flecainide — an electrophysiological interaction.
- Beta blockers and calcium channel blockers may exaggerate hypotension or bradycardia.
- Nitrates and other vasodilators produce additive vasodilation, leading to dizziness and hypotension.
- Hepatically metabolised drugs — statins, certain antidepressants, certain anticonvulsants — may show altered metabolism under the methylation and hepatic load of a lipotropic. The effect is typically mild but relevant in compromised hepatic function.
- High-dose niacin or other hepatically active compounds may produce additive hepatic stress.
- Pyridoxine (B6) can reduce the effectiveness of levodopa given without carbidopa.
- Stimulant plus CNS-active agents — SSRIs, antipsychotics — may produce unpredictable stimulation or anxiety.
- Adverse-interaction cluster to monitor for: tachycardia, palpitations, and elevated blood pressure together, indicating a cardiovascular interaction.
- Adverse-interaction cluster to monitor for: anxiety or agitation, insomnia, and headache together, indicating a CNS interaction.
- Note: the pyridoxine interaction appears in the list while pyridoxine appears nowhere in the declared formulation. Either the declaration is incomplete or the interaction belongs to a B-complex-containing formula; neither reading can be confirmed.
- Note: no constituent quantities are declared. A stimulant interaction list of this length is difficult to act on without a dose for the sympathomimetic component.
- Note: the standalone L-Carnitine entry carries an epilepsy contraindication — increased seizure frequency — that applies here too, since L-carnitine is a declared constituent, and anticonvulsant metabolism is already listed as an interaction above.
Side effects
- Reaction where you inject — redness, swelling, itching.
- A faster heart rate.
- Jitteriness.
- Anxiety.
- Irritability.
- Sweating.
- Raised blood pressure.
- Insomnia, or smaller disturbances to sleep.
- Heart palpitations.
- A change in the smell of your body odour.
- Note: several of these — fast heart rate, palpitations, raised blood pressure, anxiety, insomnia, headache — are the same symptoms the interaction section tells you to treat as warning signs when they appear together. On their own and mild, they are expected effects. In clusters, treat them as signals of an interaction going wrong.
- Injection site reaction: erythema, swelling, pruritus.
- Tachycardia.
- Jitteriness.
- Anxiety.
- Irritability.
- Sweating.
- Elevated blood pressure.
- Insomnia or lesser sleep disturbance.
- Palpitations.
- Altered body odour.
- Note: the cardiovascular and CNS entries here overlap exactly with the two adverse-interaction clusters defined above. The distinction is between isolated mild effects and co-occurring ones, not between different symptoms.
- Note: no injection-site pain is documented, which is consistent with lidocaine being in the formula rather than with the route being painless.
User reports
User reports are individual experiences submitted by site visitors. They are not medical advice, are not verified for accuracy, and do not reflect Amino Reference's views. Read the evidence section above and talk to a clinician. Full disclaimer.
Stacking
Not a stack — the alternative. Lipo-C is the same schedule and much of the same formula without the stimulant, and without the long interaction list that comes with it.
The non-stimulant sibling: shared methionine, choline, and L-carnitine, with dexpanthenol in place of ATP, Eria jarensis, and inositol. Identical dosing schedule. The obvious de-escalation for anyone who does not tolerate the sympathomimetic arm.
The stronger product in the same line. LIPO C+ is somewhat less potent. Do not run them together — both carry stimulants, and combining stimulants is warned against.
The escalation in the same line, with albuterol in place of Eria jarensis. The stimulant interaction list names albuterol, so co-administration of these two products directly contradicts it.
One of the ingredients already in this vial, also sold on its own. Its standalone entry carries additional warnings, including for epilepsy.
A declared constituent at an undisclosed dose. The standalone entry's contraindication set — epilepsy in particular — and its stimulant-interaction caution are directly relevant to a formulation that already pairs carnitine with a sympathomimetic.
Dosing figures have been reviewed and units are recomputed from the stated protocol.